16Jan 2025
Mepolizumab Reduces Asthma Exacerbations in Allergic-Eosinophilic Phenotypes

Mepolizumab Reduces Asthma Exacerbations in Allergic-Eosinophilic Phenotypes

A post hoc analysis of the REALITI-A study demonstrated that mepolizumab reduced asthma exacerbations in patients with severe asthma and both allergic and eosinophilic phenotypes. The reduction in clinically significant exacerbations was observed across all IgE levels, atopic status, and eosinophil count thresholds, supporting mepolizumab's real-world effectiveness in this patient population.

  • #pulmonology

Like

Save

Share